Treatment of intrabony periodontal defects using rhFGF‐2 in combination with deproteinized bovine bone mineral or rhFGF‐2 alone: A 6‐month randomized controlled trial

Abstract

AimTo evaluate the use of recombinant human fibroblast growth factor (rhFGF)‐2 in combination with deproteinized bovine bone mineral (DBBM) compared with rhFGF‐2 alone, in the treatment of intrabony periodontal defects.Materials and MethodsPatients with periodontitis who had received initial periodontal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rhFGF‐2 + DBBM (test) or rhFGF‐2 alone (control). Clinical parameters and a patient‐reported outcome measure (PROM) were evaluated at baseline and at 3 and 6 months postoperatively.ResultsTwenty‐two sites in each group were evaluated. A significant improvement in clinical attachment level (CAL) from baseline was observed in both groups at 6 months postoperatively. CAL gain was 3.16 ± 1.45 mm in the test group and 2.77 ± 1.15 mm in the control group, showing no significant difference between groups. Radiographic bone fill was significantly greater in the test group (47.2%) than in the control group (29.3%). No significant difference in PROM between groups was observed.ConclusionsAt 6 months, no significant difference in CAL gain or PROM between the two treatments was observed, although combination therapy yielded an enhanced radiographic outcome.

Periodontal surgery using rhFGF‐2 with deproteinized bovine bone mineral or rhFGF‐2 alone: 2‐year follow‐up of a randomized controlled trial

“…Since 2016, rhFGF-2 has been used as a novel periodontal regenerative therapy in Japan (Saito et al, 2019).…”

Treatment of Chronic Periodontitis with Recombinant Human Fibroblast Growth Factor-2 and Deproteinized Bovine Bone Mineral in Wide Intrabony Defects:12-month Follow-up Case Series

“…In an earlier randomized control trial, our research group reported that combination therapy with rhFGF-2 and DBBM enhanced RBF compared with rhFGF-2 alone at 6 months postoperatively 20) . However, information is limited concerning longitudinal clinical outcomes with such therapy.…”

“…Use of 0.3% recombinant human fibroblast growth factor (rhFGF)-2 for periodontal regeneration received formal approval in Japan in 2016 20) . Recombinant human fibroblast growth factor-2 stimulates proliferation, differentiation, and angiogenesis in a variety of cells, and has been reported to be effective in regenerating periodontal tissue in animal models 14,27) .…”

“…Furthermore, one randomized controlled clinical trial showed that the use of rhFGF-2 resulted in a greater degree of radiographic evidence of bone fill than the use of EMD in intrabony defects 11) . Recently, our research group showed that the combined use of rhFGF-2 and DBBM yielded an enhanced radiographic outcome compared to rhFGF-2 alone at 6 months postoperatively in the treatment of intrabony defects 20) . These findings suggest that combination therapy with rhFGF-2 and DBBM is an effective treatment modality.…”

Conditioned medium derived from FGF-2-modified GMSCs enhances migration and angiogenesis of human umbilical vein endothelial cells

“…However, our proposed strategy is to promote the concentration of FGF2 and other proangiogenic factors in the CM, while the application of the CM is controllable. Recombinant human fibroblast growth factor (rhFGF)-2 has been used clinically in periodontal regeneration therapy [45], whereas FGF-2modified MSC-derived CM provides some advantage over exogenous supplement of FGF-2 into the CM in that FGF-2-modified GMSCs not only produce and release more FGF-2, but also more VEGF-A, and TGF-β vs primary GMSCs. Briefly, an optimized conditioned medium by overexpressing the FGF-2 gene potentiates the angiogenic ability of hGMSCs.…”